CA2616517A1 - Abl kinase inhibition - Google Patents

Abl kinase inhibition Download PDF

Info

Publication number
CA2616517A1
CA2616517A1 CA002616517A CA2616517A CA2616517A1 CA 2616517 A1 CA2616517 A1 CA 2616517A1 CA 002616517 A CA002616517 A CA 002616517A CA 2616517 A CA2616517 A CA 2616517A CA 2616517 A1 CA2616517 A1 CA 2616517A1
Authority
CA
Canada
Prior art keywords
compound
abl
patient
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002616517A
Other languages
English (en)
French (fr)
Inventor
John Pollard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2616517A1 publication Critical patent/CA2616517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002616517A 2005-07-26 2006-07-26 Abl kinase inhibition Abandoned CA2616517A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70277105P 2005-07-26 2005-07-26
US60/702,771 2005-07-26
US78516106P 2006-03-23 2006-03-23
US60/785,161 2006-03-23
US83025706P 2006-07-12 2006-07-12
US60/830,257 2006-07-12
PCT/US2006/028984 WO2007014250A2 (en) 2005-07-26 2006-07-26 Abl kinase inhibition

Publications (1)

Publication Number Publication Date
CA2616517A1 true CA2616517A1 (en) 2007-02-01

Family

ID=37683933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002616517A Abandoned CA2616517A1 (en) 2005-07-26 2006-07-26 Abl kinase inhibition

Country Status (6)

Country Link
US (1) US20090298844A1 (cg-RX-API-DMAC7.html)
EP (1) EP1906967A4 (cg-RX-API-DMAC7.html)
JP (2) JP2009502937A (cg-RX-API-DMAC7.html)
AU (1) AU2006272609A1 (cg-RX-API-DMAC7.html)
CA (1) CA2616517A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007014250A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065124A2 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting complex karyotypes
EP2051737A2 (en) * 2006-07-26 2009-04-29 Merck & Co., Inc. A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341133A1 (en) * 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
BRPI0515012A (pt) * 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso

Also Published As

Publication number Publication date
WO2007014250A8 (en) 2008-02-21
JP2009502937A (ja) 2009-01-29
EP1906967A2 (en) 2008-04-09
EP1906967A4 (en) 2010-07-28
WO2007014250A3 (en) 2007-06-28
US20090298844A1 (en) 2009-12-03
JP2012158616A (ja) 2012-08-23
WO2007014250A2 (en) 2007-02-01
AU2006272609A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
JP2012158616A (ja) Ablキナーゼ阻害
JP2023512040A (ja) 化合物及びその使用
AU2013223713C1 (en) Oxazolidin- 2 -one compounds and uses thereof as PI3Ks inhibitors
US10047078B2 (en) Aminothiazole compounds
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
WO2018014852A1 (zh) 作为异柠檬酸脱氢酶抑制剂的化合物及其应用
CA2632256A1 (en) Combination of an iap-inhibitor and a taxane7
EP3782998A1 (en) Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
JP2016500118A (ja) ヘテロアリールアルキン化合物及びその応用
EP3137117A1 (en) Combination therapies targeting mitochondria for cancer therapy
BR112018001688B1 (pt) Uso de um composto
JP6404944B2 (ja) ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体
KR20210019422A (ko) 암 치료 방법
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
AU2017326029B2 (en) Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof
US11919899B2 (en) Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
KR20140022431A (ko) 신경섬유종증의 치료를 위한 피리미딜아미노벤즈아미드 유도체
KR101276425B1 (ko) 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물
US12421221B2 (en) Heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same
JP7289961B1 (ja) がん治療のための併用療法
WO2026080869A1 (en) Macrocyclic ras inhibitors
US20160367555A1 (en) Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease
HK1196537A (en) N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl]-1h-indazol-6-ylsulfanyl)-benzamide for the treatment of chronic myelogenous leukemia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130726